Erste Asset Management’s Fate Therapeutics FATE Stock Holding History

Erste Asset Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,700	Closed	-$147K	–	560
2023 Q2	$147K	Hold	30,700	–	–	﹤0.01%	505
2023 Q1	$163K	Hold	30,700	–	–	﹤0.01%	505
2022 Q4	$307K	Hold	30,700	–	–	0.01%	457
2022 Q3	$686K	Hold	30,700	–	–	0.02%	386
2022 Q2	$764K	Buy	30,700 +10,000	+48%	+$276K	0.02%	388
2022 Q1	$825K	Buy	20,700 +9,500	+85%	+$368K	0.02%	378
2021 Q4	$663K	Sell	11,200 -6,000	-35%	-$340K	0.01%	403
2021 Q3	$1.03M	Hold	17,200	–	–	0.02%	337
2021 Q2	$1.53M	Hold	17,200	–	–	0.03%	313
2021 Q1	$1.27M	Sell	17,200 -5,500	-24%	-$527K	0.03%	318
2020 Q4	$2.1M	Buy	+22,700	New	+$1.41M	0.06%	259

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Erste Asset Management's FATE Position: Q3 2023 in Review

Erste Asset Management sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 30,700 shares — an estimated $147K sold.

Erste Asset Management first reported a position in FATE in Q4 2020 and held it in 11 quarters. The position peaked at $2.1M in Q4 2020. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

Erste Asset Management reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
Erste Asset Management sold 30,700 Fate Therapeutics shares in Q3 2023, an estimated $147K.
Erste Asset Management first reported a position in Fate Therapeutics in Q4 2020 and held it in 11 quarters.
Erste Asset Management's Fate Therapeutics position peaked at $2.1M in Q4 2020.
170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Erste Asset Management's 13F filing for Q3 2023, filed 26 Nov 2024.